ViGenCell바이젠셀
308080 · KOSDAQ · ₩308080 · 바이젠셀
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩3,400
vs the current price (₩4,870)
- Enterprise value
- ₩47B
- Equity value
- ₩70B
- WACC
- 8.9%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Bear / Base / Bull
- Bear
- ₩3,570
- −26.7%
- Base
- ₩3,400
- −30.2%
- Bull
- ₩2,968
- −39.1%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (−20.0%).
Revenue growth
- -10%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.
- -6.7%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.
- -3.5%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.
- -0.2%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 1 years' revenue growth (-91.9% a year, annual reports), fading to 3% by year 5.
Business
- -20%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 6,372.1%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 3,215.8%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- -10%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.01%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-30.
- 0.89
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.83, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.51%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩922M
- Net debt (borrowings and leases − cash and deposits)
- −₩22B
- + Stakes and investments
- ₩800M
- Associates, long-term financial assets and deposits (book value)
- Shares
- 20,499,260
- Share price
- ₩4,870
- Market cap
- ₩100B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩0 | ₩279M | ₩23M | ₩830M | ₩774M | ₩747M | ₩746M | ₩768M |
| Growth | — | — | −91.9% | −10.0% | −6.7% | −3.5% | −0.2% | 3.0% |
| EBIT | −₩20B | −₩15B | −₩17B | −₩166M | −₩155M | −₩149M | −₩149M | −₩154M |
| EBIT margin | — | −5,487.2% | −75,453.1% | −20.0% | −20.0% | −20.0% | −20.0% | −20.0% |
| After-tax EBIT | −₩14B | −₩11B | −₩12B | −₩120M | −₩112M | −₩108M | −₩108M | −₩111M |
| + Depreciation | ₩3.3B | ₩3B | ₩2.6B | ₩53B | ₩49B | ₩48B | ₩48B | ₩49B |
| − Capital spending | — | — | ₩729M | ₩27B | ₩25B | ₩24B | ₩24B | ₩25B |
| − Working capital | −₩61B | ₩135M | −₩981M | ₩9.2M | ₩5.6M | ₩2.7M | ₩149,418 | −₩2.2M |
| Free cash flow | — | — | −₩9.5B | ₩26B | ₩24B | ₩23B | ₩23B | ₩24B |
| Discount factor | — | — | — | 0.918 | 0.843 | 0.774 | 0.711 | 0.653 |
| Present value | — | — | — | ₩24B | ₩21B | ₩18B | ₩17B | ₩16B |
Terminal value −₩74B, worth −₩48B today: -103% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩1,892 a share)Now 2.57× | ₩1,8620.98× | ₩2,9381.55× | ₩5,8943.11× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 7.9% | ₩3,434 | ₩3,230 | ₩2,992 | ₩2,710 | ₩2,371 |
| 8.4% | ₩3,589 | ₩3,417 | ₩3,217 | ₩2,983 | ₩2,706 |
| 8.9% | ₩3,718 | ₩3,569 | ₩3,400 | ₩3,204 | ₩2,974 |
| 9.4% | ₩3,823 | ₩3,695 | ₩3,550 | ₩3,383 | ₩3,191 |
| 9.9% | ₩3,911 | ₩3,799 | ₩3,673 | ₩3,531 | ₩3,367 |
Now (TTM)
- Market cap
- ₩100B
- Enterprise value
- ₩78B
- P/E
- —
- P/B
- 2.6×
- P/S
- 108.3×
- EV/EBITDA
- —
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩9,750 | ₩2,500 | ₩5,850 | ₩7,120 | ₩18,463 |
| Market cap | ₩200B | ₩51B | ₩120B | ₩146B | ₩378B |
| P/E | — | — | — | — | — |
| P/B | 4.6× | 0.9× | 1.7× | 1.6× | 3.6× |
| P/S | 8,814.7× | 183.7× | — | — | — |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 0.0% | — | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| ViGenCell | — | 2.6× | 108.3× | — | 0.0% |
| Samsung Biologics | 31.9× | 7.6× | 13.9× | — | 0.0% |
| Celltrion | 27.9× | 2.5× | 9.0× | — | 0.0% |
| Alteogen | 79.4× | 28.6× | 60.3× | — | 0.1% |
| SK biopharmaceuticals | 15.2× | 6.0× | 7.1× | — | 0.0% |
| Yuhan | 23.2× | 2.3× | 2.4× | 30.2× | 0.8% |
| HLB | — | 15.4× | 54.3× | — | 0.0% |
| Similar companies (median) | 27.9× | 6.8× | 11.4× | 30.2× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: ViGenCell / 바이젠셀 / 308080 / KRX:308080
Source: KRX statistical information